GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education.
MISSISSAUGA, ON, June 6, 2025 /CNW/ – GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country.
Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap.
Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies.
'As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges,' said Michelle Horn, Country Medical Director, GSK Canada. 'Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred.'
Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include:
Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers
Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations
Leveraging digital health tools and technology to support clinical decision-making and personalized outreach
Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers
Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services
Implementing science methodologies to ensure successful and scalable solutions across regions and populations
This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies.
'As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries,' said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. 'PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally.'
Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also:
Provide funding to support new interdisciplinary projects with direct policy and practice implications
Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows
Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention
Establish a network of community pharmacies engaged in research, data collection and pilot projects
Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders
Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public
Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development.
'Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare,' added Michelle Horn, Country Medical Director, GSK Canada. 'We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health.'
Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application.
PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation.
About the University of Waterloo School of PharmacyThe School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes.
About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at www.ca.gsk.com/en-ca.
Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
a day ago
- New Straits Times
WHO: Covid-19 origins still unknown, all theories remain open
GENEVA: All hypotheses on how the Covid-19 pandemic began remain open, the World Health Organization said Friday, following an inconclusive four-year investigation that was hamstrung by crucial information being withheld. The global catastrophe killed an estimated 20 million people, according to the WHO, while shredding economies, crippling health systems and turning people's lives upside-down. The first cases were detected in Wuhan in China in late 2019, and understanding where the SARS-CoV-2 virus that causes Covid came from is seen as key to preventing future pandemics. However, a lengthy investigation launched by the UN's health agency said that pending further data, the origins of Covid and how it first spread would remain inconclusive. "As things stand, all hypotheses must remain on the table, including zoonotic spillover and lab leak," WHO chief Tedros Adhanom Ghebreyesus told a press conference, referring to the two main hypotheses as to how the pandemic began. After much delay, a WHO team of experts went to Wuhan in January 2021 to look into the origins of the virus in cooperation with their Chinese counterparts. Their March 2021 joint report concluded that the most likely hypothesis was that the virus jumped from bats to humans via an intermediate animal. They also deemed the theory that it might have escaped from Wuhan's virology laboratories "extremely unlikely." However, that investigation faced harsh criticism for lacking transparency and access, and for not evaluating the lab-leak theory seriously. Tedros launched another investigation, setting up the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) in July 2021. The report by the group of 27 experts was published on Friday. "Until further requests for information are met, or more scientific data becomes available, the origins of SARS-CoV-2 and how it entered the human population will remain inconclusive," SAGO chair Marietjie Venter said at the press conference. She added that it was "not yet clear" if the Wuhan seafood market was where the virus first spilled over into humans. As for lab leak theories, she said much of the information needed to assess this hypothesis had not been made available, so it "could not be investigated, or excluded." "Over the past five years, we have learned a lot about Covid-19 but there is one crucial question about the pandemic that we have not yet answered: how it started," Tedros said. He said SAGO had advanced understanding of the origins of Covid-19 but much of the information needed to evaluate fully all the hypotheses had not been provided. "Despite our repeated requests, China hasn't provided hundreds of viral sequences from individuals with Covid-19 early in the pandemic, more detailed information on animals sold at markets in Wuhan, and information on work done and biosafety conditions at laboratories in Wuhan," he said. "WHO is also aware of intelligence reports performed by other governments around the world on the origins of Covid-19. We have also requested access to those reports." US President Donald Trump's administration has officially embraced the lab leak theory. Tedros said finding out how Covid-19 started was a moral imperative for the sake of those who lost their lives in the pandemic. He also said the virus was continuing to evolve, take lives and leave people suffering with post-Covid conditions, or so-called long Covid.
New Straits Times
a day ago
- New Straits Times
New feline front in Sarawak's rabies battle but complacency is greatest enemy
THE menace of human rabies in Sarawak continues to dog efforts to contain and eradicate it. Since the first cases were detected in 2017, the potentially fatal outbreak usually caused through dog bites has unfortunately spread across the entire state. Several fatalities are reported each year. As if the potential for rabies to become endemic is not worrisome enough, the first cases of rabies from cat scratches have been reported. Kuching City South Mayor Datuk Wee Hong Seng revealed in early April a rabies-positive case involving a cat out of eight cases state-wide from March 28 to April 6. Four of these rabies cases were reported in Kuching. Although the case involving a stray cat was by no means the first such case, Wee said it should alert people to be more vigilant against the disease. There have been campaigns to catch stray dogs and for the mass-vaccination of pet dogs so as to contain the spread of the disease in humans, but no similar campaigns of rounding up stray cats and vaccinating felines have taken place. The greatest enemy in the anti-rabies exercise may well be public complacency. Since reported cases of human infection are relatively few, the community is easily lulled into thinking the rabies scourge is contained. Greater resources ought to be committed towards creating greater general awareness of the disease, its symptoms and the importance of early treatment to avoid succumbing to it. With the horrors of the Covid-19 pandemic still fresh in public memory and the threat of the mass spread of life-threatening viruses becoming increasingly prevalent, efforts must be redoubled to nip potential new public-health crises in the bud. Although it is too late to put the rabies genie back into the bottle, lessons must be identified and remedies thought up so the state will be well-prepared for the next such public health threat. Perhaps the special high-level state ad-hoc committee that springs into action in the event of any public emergency, such as a natural or public-health disaster, needs to be institutionalised as a professionally run rapid-reaction agency that swiftly contains health threats. Kuching is not just famed for its ubiquitous cat statues but stray cats roaming its streets, sustained by residents leaving food for them. Cat-lovers — both locals and visitors — stop to admire the street felines, taking pictures with them and invariably even patting them. Should there be an uptick in cases of cat-borne rabies in Kuching or other parts of the state, public attention must be stepped up to highlight the health risks posed by public affection lavished on cats. It will, of course, be deeply disappointing if there comes the time when the animal that is Kuching's mascot gets closely associated with a dreaded disease. The public and officials alike must all do their utmost to avoid such a terrible eventuality. Unfortunately, complacency will only make that eventuality inevitable. Related Articles Nation Jan 22, 2025 @ 9:37am Sarawak enforces new anti-rabies vaccination order Nation Mar 29, 2025 @ 3:06am Sarawak records 11 new rabies cases in March Politics May 11, 2025 @ 2:36am Zahid to Umno: No room for complacency, bigger battles ahead Nation Apr 17, 2025 @ 8:00pm Promising results, but an uphill battle for 'climate warriors'
The Sun
2 days ago
- The Sun
Health ministry and state leaders unite to improve public health in Malaysia
PUTRAJAYA: The Health Ministry (MOH) and state health executive councillors convened today to discuss key health initiatives, including development projects, human resource strategies, and pressing public health concerns. The meeting, led by Health Minister Datuk Seri Dr Dzulkefly Ahmad, aimed to strengthen collaboration between federal and state governments for a more robust national healthcare system. According to a ministry statement, discussions covered the progress of development projects under Rolling Plan 5 (RP5) of the 12th Malaysia Plan (12MP). Efforts to improve healthcare service delivery were also reviewed, ensuring alignment between federal policies and state-level execution. Key public health issues requiring joint coordination were highlighted, including COVID-19 management, dengue prevention, sugar intake reduction, tobacco control, mental health support, and the Measles-Rubella immunisation campaign. The meeting emphasised shared accountability in tackling complex health challenges through policy coordination and information exchange. This regular engagement serves as a vital platform for fostering consensus among stakeholders, ensuring cohesive strategies to enhance Malaysia's healthcare framework.
